InflaRx N.V. (IFRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
IFRX Stock Price Chart Interactive Chart >
IFRX Price/Volume Stats
| Current price | $1.47 | 52-week high | $5.69 |
| Prev. close | $1.34 | 52-week low | $1.29 |
| Day low | $1.37 | Volume | 118,100 |
| Day high | $1.48 | Avg. volume | 222,529 |
| 50-day MA | $1.76 | Dividend yield | N/A |
| 200-day MA | $3.02 | Market Cap | 64.98M |
InflaRx N.V. (IFRX) Company Bio
Fireman B.V. (InflaRx) operates as a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. The company is based in Jena, Germany.
Latest IFRX News From Around the Web
Below are the latest news stories about InflaRx NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.
InflaRx (IFRX) Presents At Annual SVB Leerink Global Health ConferenceThe following slide deck was published by InflaRx N.V. in conjunction with this event.... |
H.C. Wainwright Maintains a Buy Rating on InflaRx (IFRX)H.C. Wainwright analyst Edward White maintained a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $11.00. The company's shares closed last Tuesday at $3.45. According to TipRanks.com, White 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 32.1% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Aeglea Biotherapeutics. The the analyst consensus on InflaRx is currently a Moderate Buy rating. |
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell CarcinomaIn vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concernsSteering Committee unanimously voted to continue study as planned and open enrollment for second dosing cohortEnrollment is also ongoing in vilobelimab monotherapy arm, with no safety concerns identified JENA, Germany, Feb. 16, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-i |
InflaRx to Present at Annual SVB Leerink Global Health ConferenceJENA, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at the 11th Annual SVB Leerink Healthcare Conference being held virtually February 14-18, 2022. Thomas Taapken, Chief Financial Officer of InflaRx, and Jordan Zwick, Chief Strategy Officer, will participate in a fireside chat moderated by an SVB Leerink research analyst on Thursday, Febr |
H.C. Wainwright Sticks to Its Buy Rating for InflaRx (IFRX)In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on InflaRx (IFRX – Research Report), with a price target of $11.00. The company's shares closed last Thursday at $3.33. According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -3.2% and a 30.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for InflaRx with a $11.00 average price target. |
IFRX Price Returns
| 1-mo | -13.02% |
| 3-mo | -51.16% |
| 6-mo | -71.06% |
| 1-year | -53.18% |
| 3-year | -95.98% |
| 5-year | N/A |
| YTD | -69.12% |
| 2021 | -5.37% |
| 2020 | 27.02% |
| 2019 | -89.11% |
| 2018 | 73.60% |
| 2017 | N/A |
Loading social stream, please wait...